Article

Inhibition of SARS-CoV-2 infection (previously 2019-nCoV) by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion

2020-03-12

Abstract excerpt

The recent outbreak of coronavirus disease (COVID-19) caused by SARS-CoV-2 infection in Wuhan, China has posed a serious threat to global public health. To develop specific anti-coronavirus therapeutics and prophylactics, the molecular mechanism that underlies viral infection must first be confirmed. Therefore, we herein used a SARS-CoV-2 spike (S) protein-mediated cell-cell fusion assay and found that SARS-CoV-2...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 3f6d9f54-b294-52ca-96a1-83d85860c346
DOI: 10.1101/2020.03.09.983247

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Inhibition of SARS-CoV-2 infection (previously 2019-nCoV) by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusionDOI 10.1101/2020.03.09.983247Read

Discovery of New Fusion Inhibitor Peptides against SARS-CoV-2 by Targeting the Spike S2 SubunitSemantic proximity Read

Design and characterization of novel SARS-CoV-2 fusion inhibitors with N-terminally extended HR2 peptidesSemantic proximity Read

Targeting an evolutionarily conserved “E-L-L” motif in the spike protein to develop a small molecule fusion inhibitor against SARS-CoV-2Semantic proximity Read

Nanomolar inhibition of SARS-CoV-2 infection by an unmodified peptide targeting the pre-hairpin intermediate of the spike proteinSemantic proximity Read

Structural and functional basis for pan-CoV fusion inhibitors against SARS-CoV-2 and its variants with preclinical evaluationSemantic proximity Read

Spike Glycoprotein Is Central to Coronavirus Pathogenesis-Parallel Between m-CoV and SARS-CoV-2Semantic proximity Read

Research Progress on Spike-Dependent SARS-CoV-2 Fusion Inhibitors and Small Molecules Targeting the S2 Subunit of SpikeSemantic proximity Read

An engineered recombinant protein containing three structural domains in SARS-CoV-2 S2 protein has potential to act as a pan-human coronavirus entry inhibitor or vaccine antigenSemantic proximity Read

Peptide derived nanobody inhibits entry of SARS-CoV-2 variantsSemantic proximity Read

A macrocyclic peptide-based fusion inhibitor targeting SARS-CoV-2 Spike S2 subunitSemantic proximity Read

Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike proteinSemantic proximity Read

SARS-CoV-2 Entry Inhibitors: Small Molecules and Peptides Targeting Virus or Host CellsSemantic proximity Read